Biopharma Finder was used to deconvolute the drug substance and idenNfy the CQAs during the discovery phase (Phase I) of the workflow. The deconvoluNon se}ngs for both the SEC and SCX workflows are described in Table . Aper idenNficaNon of the CQAs during the discovery phase, an intact workbook was created within Biopharma Finder containing the CQAs idenNfied including idenNty, theoreNcal and experimental masses, retenNon Nme and m/z values of the top 4 most intense charge states. A separate workbook was created for both the SEC and SCX studies. These workbooks were imported into Chromeleon CDS to create the processing methods that were used to idenNfy and quanNfy the CQAs during the monitoring phase of the workflow. Composite scoring on MS results was introduced for intact protein deconvoluNon mass accuracy to confirm the idenNficaNon using a tolerance of 25 ppm with excepNon of the dimer idenNficaNon, where a maximum mass tolerance of 100 ppm was applied. Output mass range (Da) 10,000-130,000 10,000-80,000